Status:
COMPLETED
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
Lead Sponsor:
Imperial College Healthcare NHS Trust
Conditions:
End-stage Renal Failure
Graft Rejection
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal \& Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal anti...
Detailed Description
1. Purpose of Study: The current immunosuppressive regime used as anti-rejection therapy after kidney transplantation in the West London Renal \& Transplant Centre at Imperial College Healthcare N...
Eligibility Criteria
Inclusion
- Live donor kidney transplant recipients
- heart-beating-Deceased donor kidney transplant recipients
- Patients suitable for induction therapy with Alemtuzumab
Exclusion
- Recipients of Non-heart-beating deceased donor kidney transplants
- Recipients of simultaneous kidney/pancreas transplants
- ABO incompatible/desensitized transplant recipients
- Positive flow cross-match/desensitized transplant recipients
- Patients with heavy prior exposure to myelosuppressive therapy
- Patients with previous malignancy
- Patients with HIV,Hepatitis-C, or Hepatitis-B infection
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00807144
Start Date
December 1 2008
End Date
March 1 2012
Last Update
August 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West London Renal & Transplant Centre, Hammersmith Hospital
London, United Kingdom, W12 0HS